



Quercetin relieves coronary atherosclerosis via regulating fibroblast growth factor 2

Rui Shi, Zhaozheng Liu, Jinzhu Yin, Yue Deng*

Department of Cardiology, Changchun University of Chinese Medicine, Changchun, Jilin, 130117, China

ARTICLE INFO

Original paper

Article history:

Received: August 27, 2023

Accepted: December 22, 2023

Published: December 31, 2023

Keywords:

Coronary artery disease, atherosclerosis, quercetin, fibroblast growth factor 2, vascular smooth muscle cells

ABSTRACT

This study aims to investigate the role of quercetin in coronary atherosclerosis and explore its possible mechanisms. Hematoxylin-eosin (H&E), immunohistochemical (IHC), and aniline blue staining were used to analyze the pathological changes in the cross-section of the aorta. Traditional Chinese Medicine Systems Pharmacology Database (TCMSP), Swiss Target Prediction, and PubChem were utilized to predict and screen the bioactive ingredients of traditional Chinese medicine (Huanglian, Yuxingcao, and Jinyinhua) for coronary atherosclerosis. Inflammatory factors and vascular protection parameters were quantitatively detected using ELISA and western blot. The proliferation and migration of vascular smooth muscle cells (VSMC) were evaluated using the Cell Counting Kit-8 (CCK-8), 5-ethynyl-2-deoxyuridine (EdU), and wound healing assays. The targets of quercetin were predicted using DisGeNET, Matascape, SWISSMODEL, cellular thermal shift assay (CETSA), and fluorescence titrimetric methods. Based on our findings, quercetin was identified as the active component of Huanglian, Yuxingcao, and Jinyinhua that exerted a positive effect on coronary atherosclerosis. In vivo and in vitro data demonstrated that quercetin improved the pathological changes in model mice and inhibited the proliferation, migration, and inflammatory response of VSMC cells. Specifically, we found that fibroblast growth factor 2 (FGF2) is a direct target of quercetin, and overexpression of FGF2 attenuated the anti-atherosclerosis function of quercetin. Overall, our study confirms the functional role of the quercetin-FGF2 axis in the progression of coronary atherosclerosis, providing a potential target for its treatment.

Doi: <http://dx.doi.org/10.14715/cmb/2023.69.15.38>

Copyright: © 2023 by the C.M.B. Association. All rights reserved.

Introduction

Coronary artery disease (CAD) is a leading cause of death from heart disease, and its incidence is rising due to an increasing population of obesity and diabetes (1, 2). According to statistics, CAD accounts for approximately 40% of all deaths-related causes in developed countries (3). CAD is a complex disease, involving a variety of mechanisms, and cell types, and is affected by a variety of risk factors, which determines that the treatment of CAD is complex and variable (4). Among them, oxidative stress and atherosclerosis are particularly closely related to the mechanism of CAD (5). At present, chemotherapy, percutaneous coronary intervention, coronary artery bypass grafting and other treatment methods are the main treatment strategy for CAD (6). However, due to the inaccuracy and incompleteness of diagnostic strategies caused by the complexity of CAD, it still has a high mortality rate. Therefore, the development of high-characteristic bio-diagnostic markers and more efficient therapeutic drugs is a problem that we urgently need to address, and it has high application value sensitivity and convenience.

Quercetin is a widely distributed, naturally occurring polyhydroxyl flavonoid found in many plant-based foods, such as red onions, apples, broccoli, parsley and berries (7, 8). It has a wide range of pharmacological properties and has been recognized as a potential drug against diabetes, hypertension, cancer and neurodegenerative diseases (9). Additionally, quercetin is also of great concern for its anti-atherosclerosis effects. Jia et al. showed that quercetin

treatment significantly reduced atherosclerotic plaque area and lipid accumulation in the aorta (10). Similarly, Cao et al. demonstrated that quercetin treatment improved atherosclerotic pathology and reduced inflammatory response in ApoE^{-/-} mice (11). Although the protective or preventive effects of quercetin on atherosclerosis have been reported, further mechanisms have not been reported yet.

In view of the fact that atherosclerosis is a common cause of CAD, we used high-fat-fed rats to simulate human atherosclerosis, exploring the protective effect of quercetin on coronary atherosclerosis in model rats. Besides, we studied the mechanism of quercetin in inhibiting proliferation, migration and inflammation in VSMC cells, and hope to find a more characteristic bio-diagnostic marker for quercetin in the treatment of coronary atherosclerosis.

Materials and Methods

Animals and experimental design

A total of 60 ApoE^{-/-} mice, weighing 180-250 g were enrolled into the research. Among them, 10 mice were fed with 1.25% high cholesterol to establish the atherosclerosis model, and the same number of mice was injected with physiological saline in equal volume as a control group. When atherosclerosis was measurable, mice were randomly divided into five groups: 1) model group (n=10, fed with 1.25% high cholesterol); 2) 25 mg/kg group (n=10, administrated with 25 mg/kg quercetin); 3) 50 mg/kg group (n=10, administrate with 50 mg/kg quercetin); 4) 100 mg/kg group (n=10, administrate with 100 mg/kg

* Corresponding author. Email: ccuemdynd@163.com

quercetin); 5) positive control group (n=10, administrate with nitroglycerin). The present study was approved by the Ethics Committee of Changchun University of Chinese Medicine.

Cell culture

Human aortic vascular smooth muscle cells (VSMCs) were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). After all the cells were resuscitated, they were cultured in RPMI-1640 medium containing 10% FBS in a humidified environment and the medium was changed every two days. When the cell growth density reached 80%, they were harvested for further analysis.

Hematoxylin-eosin (H&E) staining

The aortic tissues were fixed with formaldehyde (10%) for 24 h, and then tissues were placed in a 5% nitric acid decalcification solution for 3-5 d. After washing with water, routine dehydration, transparency, paraffin immersion, embedding and sectioning, the tissue sections were stained with hematoxylin and eosin. Finally, the pathological changes of aortic tissues were observed under microscope.

Immunohistochemical (IHC)

Paraffin-embedded aortic tissue slides were treated with 3% hydrogen peroxide containing methanol, followed by incubation with 10% goat serum to block. After washing, the sections were incubated with primary antibody against CD68 (1:500, Abcam, USA) overnight, and then secondary antibody. Subsequently, the sections were stained with DAB and visualized by microscopy (Olympus, Tokyo, Japan).

Aniline blue staining

First, aortic tissue sections were fixed in 3% buffered glutaraldehyde in 0.2 M phosphate buffer for 30 min at room temperature. Then, the samples were then stained with 5% aqueous aniline blue mixed with 4% acetic acid for 5 min. Finally, the staining was observed under a microscope (Olympus, Tokyo, Japan).

Measurement of interleukin (IL)-6 and IL-8

The concentrations of IL-6 and IL-8 in the model mice and VSMC cells were assessed using a commercially available ELISA kit (USCN Business Co., Ltd, China).

Western blot

Aortic tissues were lysed by RIPA Lysis Buffer (Solarbio, Beijing, China) and protein concentration was measured by BCA protein assay kit (Solarbio, Beijing, China). The prepared protein was separated by polyacrylamide-SDS gels and then transferred onto PVDF membranes (Roche, Switzerland). Blocked with 5% skimmed milk for 2.5 h, the PVDF membrane was subjected to incubation with primary antibodies against VEGF, Hsp70 and β -actin (1:1000, Proteintech Group Inc., Wuhan, China) at 4°C overnight. On the following day, protein samples were incubated with the secondary antibody at 37°C for 45 min. The protein blots were visualized using enhanced chemiluminescence (ECL) with exposure to X-ray films (Hyperfilm, GE Healthcare, UK, USA). β -actin was used as internal control, and the gray value ratio of the protein band to β -actin was deemed as relative protein expression.

Cell Counting Kit-8 (CCK-8)

In short, VSMC cells adjusted to the appropriate concentration (5×10^4 cells) were inoculated on 96-well plates and treated accordingly. Then, each well was added with CCK-8 solution and incubated for 2 h in the dark. Finally, the optical density at 450 nm was measured.

5-ethynyl-2-deoxyuridine (EdU) assay

Briefly, VSMC cells were inoculated in 96-well plates for 48 h. Washed with PBS (Beyotime, Beijing, China), they were incubated with 10 μ M EdU (Beyotime, Beijing, China) for 2 h at 37°C. EdU-positive cells were detected by Apollo staining and DAPI staining, and the percentage of positive cells was defined as proliferation rate.

Wound healing assay

First, VSMC cells were inoculated in a 6-well plate for 24 h. When the cells were fully fused, the pipette tip was applied to create a scratch wound on the confluent cells in the center. The migration and cell movement of the entire wound area was observed with an inverted optical microscope (Oberkochen, Germany), and the images were taken at 48 h with a camera connected to the microscope (Sony-Cyber shot, Shanghai Suoguang Visual Products Co., Ltd., China). The cell migration ability was statistically analyzed according to the cell healing.

Bioinformatics

The Traditional Chinese Medicine Systems Pharmacology Database (TCMSP, <http://ibts.hkbu.edu.hk/LSP/tcmsp.php>) was used to screen the common active ingredients of Huanglian, Yuxingcao and Jinyinhua. Swiss Target Prediction (<http://www.swisstargetprediction.ch/>) was used to predict the common targets of quercetin and coronary atherosclerosis. DisGeNET (<https://www.disgenet.org/>) and Metascape (<https://metascape.org/>) were used to further screen targets of quercetin acting on coronary atherosclerosis. PubChem (<https://pubchem.ncbi.nlm.nih.gov/>) was used to analyze the chemistry of quercetin including molecular formula, and 2D and 3D structural information. SWISSMODEL (<https://swissmodel.expasy.org/>) and Autodock (<http://www.scripps.edu/mb/olson/doc/Autodock>) were used for 3D models construction and docking study of FGF2, respectively.

Cellular thermal shift assay (CETSA)

VSMC cells treated with quercetin or DMSO at 37°C for 24 h were collected, and the cell suspension was distributed into 0.2 ml PCR tubes, with 200 μ l cell suspension in each tube. The PCR tubes were heated at the designated temperature (40, 60, 64, 67, 70, 72 and 75°C) for 3 min. They were then removed and incubated at 4°C immediately following heating. Cells were then lysed using cell lysis buffer for western (Beyotime Institute of Biotechnology) and analyzed by western blotting as described in the western blotting methods above.

Fluorescence titrimetric

Both purified F2G2 protein and quercetin samples were dissolved in PBS. The aliquots of quercetin were gradually added to two mL of F2G2 solution, and the fluorescence spectra were recorded. The resulting titration data were fitted with the Hill plot equation $y = V_{max} \times x^n / (k_n + x^n)$, and the dissociation constant (Kd) was calculated by

Origin 8.5 software.

Statistical analysis

All the data were analyzed by Statistical Package for Social Sciences 19.0 (SPSS, Chicago, IL, USA) and presented as mean \pm standard deviation (SD). Differences among the groups were analyzed by one One-way ANOVA followed by Dunnett's multiple comparisons. $P < 0.05$ were considered significant differences between groups.

Results

Construction of mice model of coronary atherosclerosis

As shown in Fig. 1A, H&E staining showed an increased necrotic area of cross-sectional aortic in the high-fat-fed mice compared to the normal-fed mice. Consistently, monocyte/macrophage content assessed by anti-CD68 IHC revealed that high-fat-fed significantly increased CD68⁺ cells (macrophages) in aortic lesions (Fig. 1B), indicating that the atherosclerosis model was successfully constructed.

Quercetin is effective in the treatment of coronary atherosclerosis in vivo

From the TCMSP database, two common ingredients of Huanglian, Yuxingcao and Jinyinhua were obtained (Fig. 2A). According to the requirement of easy absorption of the drug, quercetin was selected. Next, we obtained a total of 37 common targets of quercetin and CAD through Swiss Target Prediction, suggesting that quercetin may act on coronary atherosclerosis (Fig. 2B). The molecular structure of quercetin was shown in Fig. 2C. To further study the role of quercetin on coronary atherosclerosis, we detected the changes in the expression of inflammatory factors and vascular protective factors under the intervention of quercetin. As expected, compared to the model group, quercetin intervention significantly reduced the levels of inflammatory factors IL-6 and IL-8, and vascular protection parameters such as VEGF and HSP70




Figure 1. Construction of mice model of coronary atherosclerosis. A) H&E staining was used to observe the necrotic area of the aortic cross-section; B) The changes of inflammatory cells in the cross-section of the aorta were observed by Immunohistochemistry.




Figure 2. Quercetin is a common effective monomer of Huanglian, Yuxingcao and Jinyinhua in the treatment of coronary atherosclerosis. A) The major active components of Huanglian, Yuxingcao and Jinyinhua were predicted by TCMSP; B) The common targets of quercetin and coronary atherosclerosis were predicted by Swiss Target Prediction; C) The chemical structure of quercetin was analyzed via PubChem.




Figure 3. Quercetin is effective in the treatment of coronary atherosclerosis *in vivo*. A) The content of IL-6 and IL-8 in serum was quantitatively determined by ELISA; B) Vascular protection parameters (VEGF and HSP70) were quantitatively evaluated via western blot; C) Aortic cross-section histological analysis with Immunohistochemical; D) Aortic cross-section histological analysis with aniline blue.

were both evidently decreased (Fig. 3A and 3B). Of note, with the increase of quercetin concentration, its inhibitory effect on the above factors is also enhanced. Further, aortic cross-section histological analysis with IHC and aniline blue showed that quercetin treatment significantly reduced inflammatory cell and collagen content in a concentration-dependent manner as compared to model mice (Fig. 3C and 3D)




Quercetin inhibits VSMC proliferation, migration, and secretion of inflammatory cytokines in a dose-dependent and time-dependent manner in vitro

Quercetin showed inhibition effects on the progression of coronary atherosclerosis in model mice. To further explore the biological function of quercetin, we conducted *in vitro* studies using VSMC cells. In proliferation experiment, we found that quercetin significantly inhibited the proliferation activity of VSMC, especially at the concentration of 50 μ M (Fig. 4A). In the migration experiment, the relative migration width of the 50 μ M group was also

evidently larger than that of the other three groups (model, 2 μ M and 10 μ M) (Fig. 4B). Similarly, the levels of inflammatory cytokines IL-6 and IL-8 were remarkably reduced after quercetin treatment, especially in the 50 μ M group (Fig. 4C). The above-mentioned data confirmed that quercetin inhibited VSMC proliferation, migration and secretion of inflammatory cytokines in a dose-dependent manner. Considering that the inhibitory effect of 50 μ M quercetin is more obvious, we chose 50 μ M as a fixed dose to explore the influence of time factor on the treatment of coronary atherosclerosis. In the beginning, the weakened fluorescence activity was found in EdU staining with the increase of quercetin treatment time (Fig. 5A). Next, the wound healing data depicted that 50 μ M quercetin reduced the cell migration rate in a time-dependent manner (Fig. 5B). Meanwhile, compared with other time periods (12 h and 24 h), the content of inflammatory factors IL-6 and IL-8 in VSMC cells was the lowest after 36 h of quercetin treatment (Fig. 5C).

FGF2 is the target of quercetin on coronary atherosclerosis

To clarify the regulatory mechanism of quercetin on coronary atherosclerosis, we performed further bioinformatics analysis on the above-screened 37 targets. We screened targets related to coronary atherosclerosis through DisGeNET enrichment analysis and found these targets are mainly related to hyperlipidemia, dyslipidemias, endothelial dysfunction, vascular diseases and atherosclerosis of the aorta (Fig. 6A). After that, Metascape was applied to select the target gene related to epithelial cell proliferation and apoptosis. As presented in Fig. 6B, these genes were primarily associated with cholesterol metabolism and regulation of plasma lipoprotein particles. Of the 37 genes, we focused on FGF2, as it is related to both coronary atherosclerosis and epithelial cell proliferation and apoptosis, and has a higher expression. Its 3D structure



and possible binding patterns with quercetin are shown in Fig. 6C. To further verify whether FGF2 is the direct target of quercetin acting on coronary atherosclerosis, CETSA and fluorescence titrimetrics were conducted. CETSA data confirmed that quercetin could bind to FGF2 and promote the degradation of FGF2 protein (Fig. 6D).

FGF2 overexpression reverses the inhibitory effect of quercetin on coronary atherosclerosis

To further explore the relationship between quercetin and FGF2 in the progression of coronary atherosclerosis, we performed rescue experiments. As exhibited in Fig. 7A, compared with quercetin + pc-NC group, transfected




Figure 7. FGF2 overexpression reverses the inhibitory effect of quercetin on coronary atherosclerosis. After co-transfection with quercetin and pc-FGF2, the proliferation, migration, and secretion of inflammatory cytokines ability of VSMC cells was detected by A) CCK-8, B) EdU, C) wound healing and D) ELISA.

with quercetin + pc-FGF2 partially offset the toxic effect of quercetin on VSMC cells. Consistently, EdU results showed that the number of cell clones in group quercetin + pc-FGF2 also increased relatively as a comparison to quercetin + pc-NC group (Fig. 7B). In the verification of migration experiments, the wound healing results showed that the migration rate of VSMC cells transfected with quercetin + pc-FGF2 was significantly higher than that of cells transfected with quercetin + pc-NC (Fig. 7C). Furthermore, ELISA data depicted that overexpression FGF2 weakened the inhibition of quercetin on inflammatory response, manifested by an increase in inflammatory cytokines IL-6 and IL-8 (Fig. 7D).

Discussion

The naturally occurring pathological characteristics and typical pathogenesis of ApoE^{-/-} mice are similar to the incidence of atherosclerosis in human natural conditions and are considered to be an ideal model for the study of the pathogenesis and drug intervention of atherosclerosis (12). Therefore, in this study, we used ApoE^{-/-} mice fed a high-fat diet as an *in vivo* atherosclerosis model. Pathological manifestations of animal aorta showed obvious atherosclerosis plaque formation, lipid deposition, vascular wall thickening and hardening, reduced elasticity, and increased necrotic area (13). Similarly, in the current research, we observed pathological changes and an increase in the cross-sectional necrotic area of the aorta in model mice. Atherosclerosis is a complex chronic inflammatory disease involving the interaction of many inflammatory cells and cytokines, such as the up-regulation of adhesion molecules leading to the recruitment of immune cell vascular walls (14). In atherosclerosis lesions, the most abundant immune cell type is the macrophage, which is involved in all pathological stages of atherosclerosis by secreting chemokines (15, 16). Consistently, IHC data revealed a significant increase of CD68⁺ cells (macrophage) in the aortic lesions of mice fed with high fat, indicating that our *in vivo* simulation of atherosclerosis modeling was successful.

Many studies suggested that inflammation plays an important role in all stages of atherosclerosis development and progression (17). IL-6 is an important cytokine, that promotes the early inflammatory response of atherosclerosis, and activates the differentiation and infiltration of macrophages (12). IL-8 promotes the adhesion of mono-

cytes to arterial endothelial cells in the early stage of lesion formation and promotes angiogenesis in the later stage of plaque formation to aggravate atherosclerosis (18). Our ELISA results showed that the model mice had higher expressions of IL-6 and IL-8. Conversely, the above two inflammatory factors in the quercetin group were significantly reduced. This conclusion is consistent with Cao et al. (11). Meanwhile, we observed that quercetin inhibited the expression of inflammatory cells, again confirming the anti-inflammatory effect of quercetin. Vascular endothelial growth factor (VEGF) is a very effective pro-angiogenesis factor and it can induce the development and progression of certain pathological conditions, increase vascular permeability and recruit inflammatory cells to injury sites (19). As a member of the HSP family, HSP70 is involved in the immune response during the formation of atherosclerosis plaques, which activates inflammatory cells and reduces the stability of atherosclerosis plaques (20). Consistent with the reports, both VEGF and HSP70 were highly expressed in the model group. Terao et al. revealed that quercetin regulates blood pressure and maintains cardiovascular function by changing vascular compliance, anti-inflammatory and antioxidant effects (21). Interestingly, our data also showed that quercetin decreased the expression of vascular protective parameters VEGF and HSP70. Collagen, which forms the main component of atherosclerosis plaques, can block blood vessels and promote lipid deposition (22). Correspondingly, we observed that high-fat feeding led to higher collagen content in the aorta of model mice. Of note, quercetin improved coronary atherosclerosis by reducing aortic lesions and collagen levels, which is consistent with Li et al (23).

Accumulated evidence clearly confirms that normal quiescent VSMC proliferates intensively and migrates to the inner subcutaneous intima in the progress of atherosclerosis. More than that, the proliferation and migration of VSMC to the intima are important components of atherosclerosis (24, 25). Therefore, limiting the proliferation and migration of VSMC contributes to inhibiting the progression of atherosclerosis. The dietary flavonoid quercetin is thought to promote health, in part due to its anti-inflammatory and antioxidant properties (26). Consistent with previous studies (27, 28), quercetin, especially with a concentration of 50 μ M and a treatment time of 48h, showed similar effects in inhibiting VSMC proliferation, migration and inflammation response. Taken together, quercetin plays an anti-atherosclerosis role by inhibiting the proliferation, migration and inflammatory response of VSMC.

Fibroblast growth factor 2 (FGF-2) is an effective growth factor that stimulates the migration and proliferation of endothelial cells and promotes mitosis of VSMC (29). FGF2 is involved in the regulation of a variety of cellular functions in a variety of cell types, including cell proliferation, differentiation, viability, adhesion, and migration (30, 31). According to reports, FGF2 and its receptors have a dual role in the cardiovascular system. In the walls of normal blood vessels, the high expression of FGF2 is conducive to vascular homeostasis, vascular protection and endothelial survival. In atherosclerosis lesions, FGF2 and its receptors contribute to the inflammatory process, intimal thickening and angiogenesis in the plaque (32).

In this study, we demonstrated the anti-atherosclerosis effect of quercetin both *in vivo* and *in vitro*. Mechanically,

we confirmed that FGF2 was the target of quercetin, and overexpression of FGF2 attenuates the anti-atherosclerosis effect of quercetin. The results provide insight into the potential use of quercetin to expand a therapeutic window in the prevention of coronary atherosclerosis.

Declarations

Conflicts of interest

The authors state that there are no conflicts of interest.

Ethics approval and consent to participate

The experimental protocol was established, according to the ethical guidelines of the Helsinki Declaration and was approved by the Animal Ethics Committee of Changchun University of Chinese Medicine.

Consent for publication

The authors give consent to the publication in the journal.

Availability of data and material

All data generated or analysed during this study are included in this published article.

Funding

This project was supported by the science and technology research project of the Jilin Provincial Department of Education (JKKH20210985KJ) and Project supported by the science and technology development plan of Jilin Province (20190303166SF).

Authors' contributions

Rui Shi and Yue Deng conceived and designed the study. Rui Shi, Zhaozheng Liu and Jinzhu Yin conducted most of the experiments. Rui Shi analyzed the data. Jinzhu Yin performed the literature search and data extraction. Rui Shi drafted the manuscript. Rui Shi and Yue Deng finalized the manuscript. All authors read and approved the final manuscript.

Acknowledgments

We deeply appreciate the supports of all participants. A preprint has previously been published (33). The authors declare that the work described was original research that has not been published previously.

References

- Gao R, Yang Y, Han Y, Huo Y, Chen J, Yu B, Su X, Li L, Kuo HC, Ying SW, Cheong WF, Zhang Y, Su X, Xu B, Popma JJ, Stone GW. Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial. *J Am Coll Cardiol*. 2015;66(21):2298-2309. doi: 10.1016/j.jacc.2015.09.054.
- Timmis A, Townsend N, Gale C, Grobbee R, Maniadakis N, Flather M, Wilkins E, Wright L, Vos R, Bax J, Blum M, Pinto F, Vardas P. European Society of Cardiology: Cardiovascular Disease Statistics 2017. *Eur Heart J*. 2018;39(7):508-579. doi: 10.1093/eurheartj/ehx628.
- Zou JG, Ma YT, Xie X, Yang YN, Pan S, Adi D, Liu F, Chen BD. The association between CYP1A1 genetic polymorphisms and coronary artery disease in the Uygur and Han of China. *Lipids Health Dis*. 2014;13:145. doi: 10.1186/1476-511x-13-145.
- Kwak BR, Bäck M, Bochaton-Piallat ML, Caligiuri G, Daemen MJ, Davies PF, Hofer IE, Holvoet P, Jo H, Krams R, Lehoux S, Monaco C, Steffens S, Virmani R, Weber C, Wentzel JJ, Evans PC. Biomechanical factors in atherosclerosis: mechanisms and clinical implications. *Eur Heart J*. 2014;35(43):3013-3020, 3020a-3020d. doi: 10.1093/eurheartj/ehu353.
- Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med*. 2005;352(16):1685-1695. doi: 10.1056/NEJMra043430.
- Acharya D, Gulack BC, Loyaga-Rendon RY, Davies JE, He X, Brennan JM, Thourani VH, Williams ML. Clinical Characteristics and Outcomes of Patients With Myocardial Infarction and Cardiogenic Shock Undergoing Coronary Artery Bypass Surgery: Data From The Society of Thoracic Surgeons National Database. *Ann Thorac Surg*. 2016;101(2):558-566. doi: 10.1016/j.athoracsur.2015.10.051.
- Nishimuro H, Ohnishi H, Sato M, Ohnishi-Kameyama M, Matsunaga I, Naito S, Ippoushi K, Oike H, Nagata T, Akasaka H, Saitoh S, Shimamoto K, Kobori M. Estimated daily intake and seasonal food sources of quercetin in Japan. *Nutrients*. 2015;7(4):2345-2358. doi: 10.3390/nu7042345.
- Guo Y, Mah E, Davis CG, Jalili T, Ferruzzi MG, Chun OK, Bruno RS. Dietary fat increases quercetin bioavailability in overweight adults. *Mol Nutr Food Res* 2013;57(5):896-905. doi: 10.1002/mnfr.201200619.
- Jiang YH, Jiang LY, Wang YC, Ma DF, Li X. Quercetin Attenuates Atherosclerosis via Modulating Oxidized LDL-Induced Endothelial Cellular Senescence. *Front Pharmacol*. 2020;11:512. doi: 10.3389/fphar.2020.00512.
- Kobori M, Takahashi Y, Sakurai M, Akimoto Y, Tshushida T, Oike H, Ippoushi K. Quercetin suppresses immune cell accumulation and improves mitochondrial gene expression in adipose tissue of diet-induced obese mice. *Mol Nutr Food Res* 2016;60(2):300-312. doi: 10.1002/mnfr.201500595.
- Cao H, Jia Q, Shen D, Yan L, Chen C, Xing S. Quercetin has a protective effect on atherosclerosis via enhancement of autophagy in ApoE(-/-) mice. *Exp Ther Med*. 2019;18(4):2451-2458. doi: 10.3892/etm.2019.7851.
- Li SS, Cao H, Shen DZ, Chen C, Xing SL, Dou FF, Jia QL. Effect of Quercetin on Atherosclerosis Based on Expressions of ABCA1, LXR- α and PCSK9 in ApoE(-/-) Mice. *CHIN J Integr Med*. 2020;26(2):114-121. doi: 10.1007/s11655-019-2942-9.
- Li Y, C GZ, Wang XH, Liu DH. Progression of atherosclerosis in ApoE-knockout mice fed on a high-fat diet. *Eur Rev Med Pharmacol Sci*. 2016;20(18):3863-3867.
- Palmefors H, DuttaRoy S, Rundqvist B, Börjesson M. The effect of physical activity or exercise on key biomarkers in atherosclerosis--a systematic review. *Atherosclerosis*. 2014;235(1):150-161. doi: 10.1016/j.atherosclerosis.2014.04.026.
- Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. *Cell*. 2011;145(3):341-355. doi: 10.1016/j.cell.2011.04.005.
- Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. *Nat Rev Immunol*. 2013;13(10):709-721. doi: 10.1038/nri3520.
- Li SM, Li JG, Xu H. A New Perspective for Chinese Medicine Intervention for Coronary Artery Disease: Targeting Inflammation. *CHIN J Integr Med*. 2019;25(1):3-8. doi: 10.1007/s11655-018-2995-1.
- An Z, Li J, Yu J, Wang X, Gao H, Zhang W, Wei Z, Zhang J, Zhang Y, Zhao J, Liang X. Neutrophil extracellular traps induced by IL-8 aggravate atherosclerosis via activation NF- κ B signaling in macrophages. *Cell Cycle*. 2019;18(21):2928-2938. doi: 10.1080/15384101.2019.1662678.
- Melincovici CS, Boşca AB, Şuşman S, Mărginean M, Mişu C, Istrate M, Moldovan IM, Roman AL, Mişu CM. Vascular endothe-

- lial growth factor (VEGF) - key factor in normal and pathological angiogenesis. *Rom J Morphol Embryo*. 2018;59(2):455-467.
20. Guo F, Tang C, Li Y, Liu Y, Lv P, Wang W, Mu Y. The interplay of LncRNA ANRIL and miR-181b on the inflammation-relevant coronary artery disease through mediating NF- κ B signalling pathway. *J Cell Mol Med*. 2018;22(10):5062-5075. doi: 10.1111/jcmm.13790.
21. Terao J. Factors modulating bioavailability of quercetin-related flavonoids and the consequences of their vascular function. *Biochem Pharmacol*. 2017;139:15-23. doi: 10.1016/j.bcp.2017.03.021.
22. Mostaço-Guidolin LB, Smith MSD, Hewko M, Schattka B, Sowa MG, Major A, Ko AC. Fractal dimension and directional analysis of elastic and collagen fiber arrangement in unsectioned arterial tissues affected by atherosclerosis and aging. *J Appl Physiol* (1985).(Bethesda, Md : 1985). 2019;126(3):638-646. doi: 10.1152/jappphysiol.00497.2018.
23. Lu XL, Zhao CH, Yao XL, Zhang H. Quercetin attenuates high fructose feeding-induced atherosclerosis by suppressing inflammation and apoptosis via ROS-regulated PI3K/AKT signaling pathway. *Biomed Pharmacother*. 2017;85:658-671. doi: 10.1016/j.biopha.2016.11.077.
24. Rafieian-Kopaei M, Setorki M, Doudi M, Baradaran A, Nasri H. Atherosclerosis: process, indicators, risk factors and new hopes. *Int J Preventive Med*. 2014;5(8):927-946.
25. Sato K, Yamashita T, Shirai R, Shibata K, Okano T, Yamaguchi M, Mori Y, Hirano T, Watanabe T. *Int J Mol Sci* 2018;19(5). doi: 10.3390/ijms19051293.
26. Zhang C, Chen D, Maguire EM, He S, Chen J, An W, Yang M, Afzal TA, Luong LA, Zhang L, Lei H, Wu Q, Xiao Q. Cbx3 inhibits vascular smooth muscle cell proliferation, migration, and neointima formation. *Cardiovasc Res*. 2018;114(3):443-455. doi: 10.1093/cvr/cvx236.
27. Wang W, Wang C, Ding XQ, Pan Y, Gu TT, Wang MX, Liu YL, Wang FM, Wang SJ, Kong LD. Quercetin and allopurinol reduce liver thioredoxin-interacting protein to alleviate inflammation and lipid accumulation in diabetic rats. *Brit J Pharmacol*. 2013;169(6):1352-1371. doi: 10.1111/bph.12226.
28. Alfano D, Franco P, Stoppelli MP. Modulation of Cellular Function by the Urokinase Receptor Signalling: A Mechanistic View. *Front Cell Dev Biol*. 2022;10:818616. doi:10.3389/fcell.2022.818616.
29. Mao Y, Liu XQ, Song Y, Zhai CG, Xu XL. Fibroblast growth factor-2/platelet-derived growth factor enhances atherosclerotic plaque stability. *J Cell Mol Med*. 2020;24(1):1128-1140. doi: 10.1111/jcmm.14850.
30. Pakala R, Watanabe T, Benedict CR. Induction of endothelial cell proliferation by angiogenic factors released by activated monocytes. *Cardiovasc Radiat Med*. 2002;3(2):95-101. doi: 10.1016/s1522-1865(02)00159-2.
31. Liang W, Wang Q, Ma H, Yan W, Yang J. Knockout of Low Molecular Weight FGF2 Attenuates Atherosclerosis by Reducing Macrophage Infiltration and Oxidative Stress in Mice. *Cell Physiol Biochem*. 2018;45(4):1434-1443. doi: 10.1159/000487569.
32. Liu MH, Tang ZH, Li GH, Qu SL, Zhang Y, Ren Z, Liu LS, Jiang ZS. Janus-like role of fibroblast growth factor 2 in arteriosclerotic coronary artery disease: atherogenesis and angiogenesis. *Atherosclerosis*. 2013;229(1):10-17. doi: 10.1016/j.atherosclerosis.2013.03.013.
33. Livingston MJ, Shu S, Fan Y, et al. Tubular cells produce FGF2 via autophagy after acute kidney injury leading to fibroblast activation and renal fibrosis. *Autophagy*. 2023;19(1):256-277. doi:10.1080/15548627.2022.2072054